Immunome Inc is a biopharmaceutical company. It is engaged in utilizing proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The company's primary focus areas are oncology and infectious... Immunome Inc is a biopharmaceutical company. It is engaged in utilizing proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The company's primary focus areas are oncology and infectious disease, including COVID-19. Show more
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today provided an update on recent business development...
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointment of Phil Tsai, PhD, as...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 2.75 | 19.9854651163 | 13.76 | 16.6699 | 12.955 | 574259 | 14.90382284 | CS |
4 | 4.67 | 39.4425675676 | 11.84 | 16.6699 | 11.5 | 1008978 | 12.8320091 | CS |
12 | 1.25 | 8.19134993447 | 15.26 | 16.79 | 11.07 | 953769 | 13.63109413 | CS |
26 | 0.03 | 0.182038834951 | 16.48 | 30.958 | 11.07 | 875787 | 17.36601582 | CS |
52 | 9.47 | 134.517045455 | 7.04 | 30.958 | 6.13 | 507645 | 16.36260126 | CS |
156 | -0.1 | -0.602046959663 | 16.61 | 30.958 | 2.09 | 232969 | 14.65756181 | CS |
260 | 0.85 | 5.42784163474 | 15.66 | 63.78 | 2.09 | 235555 | 16.67741458 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.